1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window

Samankaltaisia teoksia

• 1053 Preclinical pharmacodynamic characterization of STK-026: a novel IL-12 partial agonist for cancer with maintained CD8 T cell activity, reduced NK-mediated toxicity and an improved therapeutic window
  Tekijä: Martin Oft, et al.
  Julkaistu: (2023-11-01)
• Structure-Guided Stapling of Dimeric Conformations and Linker Engineering Enhance Thermostability and Fine-Tune Activity of Bispecific VHH Cytokine Agonists
  Tekijä: Raphael Trenker, et al.
  Julkaistu: (2025-09-01)
• 228 Engineered human IL-2/IL-2Rß orthogonal pairs selectively enhance anti-GPC3 CAR T cells in vivo to drive complete responses in solid epithelial tumor models
  Tekijä: Martin Oft, et al.
  Julkaistu: (2023-11-01)
• IL-2 based cancer immunotherapies: an evolving paradigm
  Tekijä: Sushama Rokade, et al.
  Julkaistu: (2024-07-01)
• Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27
  Tekijä: Mingli Xu, et al.
  Julkaistu: (2010-01-01)